Table 1 Demographic and clinicopathologic characteristics of the study population with 1-year and 3-year PFS
Characteristics | N (%) | 1-year PFS (95% CI) | P | 3-year PFS (95% CI) | P |
|---|---|---|---|---|---|
Age | 60 (53–66) |  | 0.610 |  | 0.571 |
  ≤ 60 | 282 (52.91) | 84.75 (80.00–88.46) |  | 63.66 (57.69–69.03) |  |
  > 60 | 251 (47.09) | 86.45 (81.57–90.12) |  | 61.15 (54.68–66.98) |  |
BMI | 23.44 (21.30–25.43) |  | 0.084 |  | 0.007 |
  ≤ 23.9 | 305 (57.22) | 83.28 (78.60–87.02) |  | 57.21 (51.32–62.66) |  |
  > 23.9 | 228 (42.78) | 88.60 (83.71–92.09) |  | 69.38 (62.89–74.96) |  |
Sex | Â | Â | 0.697 | Â | 0.322 |
 Male | 413 (77.49) | 85.23 (81.43–88.31) |  | 63.56 (58.62–68.08) |  |
 Female | 120 (22.51) | 86.67 (79.16–91.61) |  | 58.63 (49.20–66.91) |  |
ASA score | Â | Â | 0.220 | Â | 0.685 |
 1 | 49 (9.19) | 81.63 (67.67–89.99) |  | 68.98 (53.86–80.01) |  |
 2 | 418 (78.42) | 84.93 (81.13–88.02) |  | 62.64 (57.73–67.15) |  |
 3 | 66 (12.38) | 92.42 (82.75–96.77) |  | 57.31 (44.46–68.22) |  |
ECOG |  |  | 0.063 |  |  < 0.001 |
 0 | 384 (72.05) | 87.24 (83.47–90.20) |  | 68.96 (64.00–73.39) |  |
  ≥ 1 | 149 (27.95) | 81.21 (73.96–86.62) |  | 46.02 (37.74–53.89) |  |
Comorbidities | Â | Â | 0.577 | Â | 0.420 |
 0 | 354 (66.42) | 86.16 (82.10–89.35) |  | 63.73 (58.40–68.56) |  |
  ≥ 1 | 179 (33.58) | 84.36 (78.15–88.92) |  | 60.02 (52.31–66.88) |  |
Location |  |  | 0.002 |  |  < 0.001 |
 Upper | 165 (30.96) | 87.27 (81.15–91.51) |  | 64.37 (56.47–71.21) |  |
 Middle | 77 (14.45) | 88.31 (78.74–93.74) |  | 62.87 (50.85–72.73) |  |
 Lower | 266 (49.91) | 86.09 (81.32–89.72) |  | 65.34 (59.17–70.82) |  |
 Diffuse | 25 (4.69) | 60.00 (38.45–76.11) |  | 18.00 (5.82–35.57) |  |
Diameter (cm) | 2 (1.5–3.5) |  |  < 0.001 |  |  < 0.001 |
  ≤ 2 | 289 (54.22) | 90.31 (86.28–93.21) |  | 75.38 (69.87–80.03) |  |
 2–5 | 190 (35.65) | 84.74 (78.79–89.13) |  | 52.28 (44.81–59.21) |  |
  ≥ 5 | 54 (10.13) | 62.96 (48.68–74.28) |  | 29.38 (17.90–41.81) |  |
Differentiation | Â | Â | 0.044 | Â | 0.080 |
 Well/Moderate | 163 (30.58) | 90.18 (84.48–93.87) |  | 67.68 (59.71–74.42) |  |
 Poor | 370 (69.42) | 83.51 (79.32–86.92) |  | 60.20 (54.95–65.04) |  |
ypT |  |  | 0.004 |  |  < 0.001 |
 T0 | 39 (7.32) | 97.44 (83.16–99.63) |  | 92.08 (77.39–97.38) |  |
 T1 | 54 (10.13) | 92.59 (81.46–97.15) |  | 81.63 (67.36–90.09) |  |
 T2 | 80 (15.01) | 91.25 (82.52–95.73) |  | 79.70 (68.99–87.05) |  |
 T3 | 119 (22.33) | 86.55 (78.99–91.54) |  | 62.60 (52.98–70.80) |  |
 T4 | 241 (45.22) | 79.67 (74.01–84.22) |  | 47.82 (41.35–53.99) |  |
ypN |  |  |  < 0.001 |  |  < 0.001 |
 N0 | 233 (43.71) | 95.71 (92.17–97.67) |  | 83.25 (77.70–87.53) |  |
 N1 | 109 (20.45) | 88.99 (81.43–93.59) |  | 68.96 (59.17–76.86) |  |
 N2 | 86 (16.14) | 81.40 (71.44–88.16) |  | 50.59 (39.49–60.67) |  |
 N3 | 105 (19.70) | 62.86 (52.87–71.30) |  | 20.80 (13.62–29.03) |  |
Resection type |  |  |  < 0.001 |  |  < 0.001 |
 Subtotal | 309 (57.97) | 89.97 (86.04–92.84) |  | 68.54 (62.95–73.48) |  |
 Total | 224 (42.03) | 79.46 (73.56–84.19) |  | 54.14 (47.29–60.49) |  |
Adjuvant chemotherapy |  |  | 0.007 |  |  < 0.001 |
 No | 96 (18.01) | 77.08 (67.32–84.27) |  | 46.68 (36.24–56.45) |  |
 Yes | 437 (81.99) | 87.41 (83.93–90.19) |  | 65.96 (61.24–70.25) |  |
Cycle of NACT | Â | Â | 0.233 | Â | 0.110 |
  ≤ 3 | 478 (89.68) | 84.94 (81.41–87.85) |  | 61.21 (56.61–65.47) |  |
  > 3 | 55 (10.32) | 90.91 (79.53–96.11) |  | 74.45 (60.70–84.00) |  |
Clavien–Dindo |  |  | 0.077 |  | 0.100 |
 0–II | 455 (85.37) | 86.59 (83.11–89.41) |  | 63.59 (58.90–67.90) |  |
 III–IV | 78 (14.63) | 79.49 (68.72–86.89) |  | 56.05 (44.26–66.28) |  |
Post-NACT CEA | 2.42 (1.63–4.21) |  |  < 0.001 |  |  < 0.001 |
  ≤ 5.72 | 447 (83.86) | 88.14 (84.77–90.81) |  | 67.48 (62.84–71.67) |  |
  > 5.72 | 86 (16.14) | 72.09 (61.32–80.34) |  | 36.59 (26.43–46.78) |  |
Post-NACT CA19-9 | 12.88 (7.24–24.64) |  |  < 0.001 |  |  < 0.001 |
  ≤ 15.00 | 311 (58.35) | 90.35 (86.49–93.15) |  | 70.88 (65.42–75.65) |  |
  > 15.00 | 222 (41.56) | 78.83 (72.85–83.64) |  | 50.58 (43.67–57.08) |  |
Post-NACT CA72-4 | 2.92 (1.54–7.12) |  |  < 0.001 |  |  < 0.001 |
  ≤ 2.60 | 244 (44.78) | 92.62 (88.55–95.29) |  | 73.29 (67.18–78.44) |  |
  > 2.60 | 289 (54.22) | 79.58 (74.46–83.79) |  | 53.31 (47.27–58.98) |  |
Post-NACT CTM |  |  |  < 0.001 |  |  < 0.001 |
 0 | 140 (26.27) | 95.71 (90.71–98.05) |  | 81.35 (73.82–86.90) |  |
 1 | 233 (43.71) | 88.84 (84.05–92.26) |  | 65.22 (58.53–71.11) |  |
 2 | 116 (21.76) | 73.28 (64.23–80.38) |  | 46.77 (37.38–55.60) |  |
 3 | 44 (8.26) | 68.18 (52.27–79.76) |  | 27.70 (15.13–41.78) |  |